Aster DM Quality Care Ltd Q3 FY2024 Concall Summary

Key Takeaways

• Overwhelming vote unlocks the story: 99.86% of eligible votes approved the GCC segregation, clearing the path for a \$903 mn upfront consideration and a planned ₹110–120 per share dividend.
• India business delivers breakout growth: Revenue rose 23% YoY to ₹949 cr, post-NCI PAT more than doubled, and mature hospital margins hit 21.7%, proving the cluster model works.
• Margin expansion is now a quantified commitment: Hospital and clinic segment EBITDA margin is targeted to expand 300–400 bps over the next two to three years, even while adding 1,700 beds.
• New hospitals are ramping faster than history: Whitefield is expected to break even within 12 months and to achieve in 3–4 years what CMI took seven years to do, with cash burn running below 40% of budget.
• What to watch next quarter: Transaction close timing, the actual dividend record date, whether labs hit their promised Q4 breakeven, and any announcement on the strategic PE partner.

The GCC Segregation & Capital Return

• Shareholder mandate was near-unanimous: 99.96% voted to approve the sale of the material subsidiary; all 20 institutional investors and 99.97% of retail holders voted in favor, leaving no ambiguity about support for the separation.
• Dividend mechanics are set: Management intends to distribute 70–80% of the \$903 mn upfront consideration as a dividend, translating to ₹110–120 per share, with the Board still evaluating uses for the remaining 20–30% including inorganic opportunities or debt reduction.
• Tax efficiency drove the choice: An extensive study concluded that a dividend is the most tax-effective method to upstream funds to both resident and non-resident shareholders, given individual tax positions.
• Closing is close: Conditions precedent are substantially progressed, with merger control approval in Saudi Arabia among the last items; management expects to close by late February or early March, targeting end of FY24.

Alisha Moopen: "Moving forward, post the successful closing of the proposed transaction, our intention, as published earlier is to distribute between 70% to 80% of the upfront consideration of \$903 million as a dividend to our shareholders. This dividend is expected to be within the range of INR 110 to INR 120 per share, subject to the necessary corporate approvals mandated by the law."

India Performance: The Growth Engine

• Revenue and profit surge: India revenue grew 23% YoY to ₹949 cr, EBITDA rose 37% to ₹168 cr with margin expanding to 17.7% from 15.9%, and post-NCI PAT more than doubled with 105% YoY growth to ₹62 cr.
• Mature hospitals are the profit anchor: Mature hospitals delivered 16% revenue growth and 26% EBITDA growth, with ROCE improving sharply from 19.2% to 27.1% and operating EBITDA margin reaching 21.7%.
• Adjusted PAT tells the clean story: Consolidated PAT post-NCI of ₹179 cr adjusts to ₹213 cr after stripping out new hospital losses (₹20 cr), operational losses from the Aster Arabia JV (₹8 cr), and one-time restructuring costs (₹6 cr), representing 53% YoY growth.
• ARPOB growth is sustainable at 8–9%: Current 9M ARPOB growth exceeds 12% from revenue assurance optimization, but this is masked by lower ARPOB (~₹20,000) from O&M asset-light hospitals; excluding those, growth is above 10%, and insurance penetration supports further expansion by enabling affordability for high-end quaternary care.
• Payor mix is favorable: Kerala carries 65% cash overall, with north Kerala above 80%; Bangalore cluster is ~40% cash. Government schemes represent only 5–6% across India, so there is no burden from large low-paying public programs.

Margin Expansion: The 300–400 bps Roadmap

• The headline commitment: Hospital and clinic segment EBITDA margin, currently 20.8% in Q3 and 20.2% for 9M, is expected to expand by at least 300–400 bps over the next two to three years, inclusive of all 1,700 planned bed additions.
• Brownfield is the margin accelerator: Adding 100 beds at Kannur (currently high-teens EBITDA margin) with no fixed cost increase will expand margin faster; similarly, Medcity's 100-bed expansion requires only nurses and junior doctors since consultants are already in place, and Whitefield is ramping far faster than CMI did.
• Occupancy is the low-hanging fruit: Current optimal capacity is 68–70%, and incremental revenue from higher occupancy flows mostly to the bottom line, making this the single biggest near-term margin lever.
• Cost optimization has further room: Material cost has already been reduced from a peak of 25% to ~20–21.5%, but management sees significant remaining scope in manpower cost and other overheads.
• No drag from expansion: Management states the expansion plan is designed to ensure no EBITDA drag; sufficient capacity exists with utilization still to improve, and cost-saving initiatives are ongoing. The only current loss-maker is Whitefield, and even that is burning less than 40% of budget.
• Consolidated margin to cross 20%: As labs and pharmacies stop their cash burn, consolidated margin is expected to grow beyond 20% in the next two to three years.

Sunil Kumar: "Including all the expansion 1,700 beds, we are looking at the next two to three years, approximately, only in the hospital and clinic segment, we are looking at least 300 to 400 basis points expansion, which is expected in the first two to three years."

Bed Expansion: 1,700 Beds by FY27

• The capacity target: Aster aims to reach over 6,600 beds by FY27, adding approximately 1,700 beds over the next three years, with 60% brownfield and 40% greenfield.
• Brownfield additions are concentrated in proven clusters: Kerala cluster, Medcity, and Karnataka hospitals will absorb the majority of brownfield beds, leveraging existing fixed costs and clinical teams.
• Greenfield enters new geographies: A 460-bed start in Trivandrum and 250 beds in Kasargod are planned, and management is actively evaluating inorganic expansion into Uttar Pradesh and Maharashtra.
• Hub-and-spoke model with format flexibility: In new geographies, Aster will pursue larger 500-bed metro hospitals; in areas where it already dominates, it is not averse to 200–300 bed hospitals, creating a combo of large and mid-sized facilities.
• Whitefield is the template for faster ramps: The 500-bed Whitefield hospital is expected to break even within 12 months of opening, with cash burn running below 40% of budget, and management aspires to achieve in 3–4 years what CMI took seven years to do, citing the clinical team, affluent location, and infrastructure.

Nitish Shetty: "If you really look at the CMI numbers, we have an aspiration to achieve CMI numbers in next three years. What CMI has done in seven years, we are looking at this hospital because of the clinical team we have, the location, where we are, and the patient mix... we are expecting to do it in 3-4 years' time, what CMI has done in 7 years."

Ecosystem Bets: Labs, Pharmacies & Asset-Light

• Labs are nearing breakeven: Management is confident the lab vertical will break even in Q4 FY24, after a period of back-end tightening and revenue enhancement following rapid scaling to 250 locations.
• Pharmacies will take longer: The pharmacy vertical may take another year or two to break even, as some locations were suboptimal and are being relocated; the focus is now on back-end areas and revenue enhancement rather than store count.
• The ecosystem logic is hospital-centric: Labs and pharmacies exist to create an integrated ecosystem around hospitals, from teleconsult to post-discharge; expansion will only happen in states and cities where Aster has hospitals, currently Karnataka, Kerala, and Telangana with 220+ pharmacies.
• The myAster app is coming to India: The app is more or less finalized and expected to launch in six months, aimed at augmenting revenue and services across the ecosystem.
• Asset-light hospitals are in observation mode: Of the four O&M asset-light hospitals deployed, 50% have done well and 50% are taking time; the model is good for ROCE though it may not generate enough EBITDA margin, and management is confident viability will be demonstrated in the next year.
• Loss drag from new initiatives is minimal: Beyond Whitefield, the two O&M asset-light hospitals that are still ramping have losses in the range of a few lakhs of rupees, not crores, and the asset-light category already achieved ~4% EBITDA margin in Q3.

Nitish Shetty: "But we are committed to this model, and we are going to keep continuing focusing on this model to strengthen our integrated healthcare ecosystem."

Strategic Direction: Top Three in Five Years

• The stated ambition: Aster's vision is to be among the top three hospital players in India within the next five years, with a focused approach post-GCC separation.
• A PE partner is being actively evaluated: Multiple PE investors have expressed interest, and the Board is evaluating options; a partner would assist primarily on the inorganic front and new edge initiatives, acting as an add-on to existing growth plans rather than a replacement for them.
• Geographic expansion is on the table: Management is actively looking at expanding into neighboring geographies and considering presence in Northern India (Uttar Pradesh) and Maharashtra through inorganic M&A.
• The model is positioned as an industry bellwether: Management believes Aster's integrated cluster model reflects what will play out across Indian healthcare in coming years, with the company as the flag bearer of that change.
• Corporate costs post de-merger are manageable: Current corporate cost is 1.4–1.5% of topline with a full leadership team already in place; another 20–30 bps impact is expected, with no major increase anticipated.

Nitish Shetty: "I think Aster reflects what is going to play out in India in the coming years, the future. What happens in Aster is going to happen in the Indian healthcare landscape across the states also. But I think we will be the flag bearer of this change and we have a conviction that this work model we have created is here to stay and to keep on going forward."

Guidance & Commitments

Key Metrics